NZ549519A - Peptides that activate the guanylate cyclase C (GC-C) receptor for treating gastrointestinal disorders - Google Patents
Peptides that activate the guanylate cyclase C (GC-C) receptor for treating gastrointestinal disordersInfo
- Publication number
- NZ549519A NZ549519A NZ549519A NZ54951905A NZ549519A NZ 549519 A NZ549519 A NZ 549519A NZ 549519 A NZ549519 A NZ 549519A NZ 54951905 A NZ54951905 A NZ 54951905A NZ 549519 A NZ549519 A NZ 549519A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cys
- pro ala
- thr gly
- asn pro
- tyr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/796,719 US7304036B2 (en) | 2003-01-28 | 2004-03-09 | Methods and compositions for the treatment of gastrointestinal disorders |
| US10/845,895 US20060281682A1 (en) | 2003-01-28 | 2004-05-14 | Methods and compositions for the treatment of gastrointestinal disorders |
| US10/899,806 US7371727B2 (en) | 2003-01-28 | 2004-07-27 | Methods and compositions for the treatment of gastrointestinal disorders |
| US11/054,071 US7772188B2 (en) | 2003-01-28 | 2005-02-08 | Methods and compositions for the treatment of gastrointestinal disorders |
| PCT/US2005/007752 WO2005087797A1 (en) | 2004-03-09 | 2005-03-08 | Methods and compositions for the treatment of gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ549519A true NZ549519A (en) | 2010-03-26 |
Family
ID=34975527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ549519A NZ549519A (en) | 2004-03-09 | 2005-03-08 | Peptides that activate the guanylate cyclase C (GC-C) receptor for treating gastrointestinal disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7772188B2 (enExample) |
| EP (2) | EP1730172A4 (enExample) |
| JP (2) | JP2008501310A (enExample) |
| KR (1) | KR101202727B1 (enExample) |
| CN (2) | CN102020704A (enExample) |
| AU (1) | AU2005222387B2 (enExample) |
| BR (1) | BRPI0508558A (enExample) |
| CA (1) | CA2558050C (enExample) |
| IL (1) | IL177772A0 (enExample) |
| MX (1) | MXPA06010205A (enExample) |
| NO (1) | NO335730B1 (enExample) |
| NZ (1) | NZ549519A (enExample) |
| SG (1) | SG153824A1 (enExample) |
| WO (1) | WO2005087797A1 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4206272B2 (ja) | 2001-03-29 | 2009-01-07 | サイナージィ ファーマスーティカルズ、インコーポレイテッド | 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト |
| ATE477268T1 (de) * | 2003-01-28 | 2010-08-15 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur behandlung von magen-darm- störungen |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2006138571A2 (en) * | 2005-06-16 | 2006-12-28 | Mohammed Saeed | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance |
| WO2007022531A2 (en) * | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1996218A4 (en) * | 2006-02-24 | 2012-07-11 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS |
| EP2650303A1 (en) * | 2007-02-26 | 2013-10-16 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of heart failure and other disorders |
| RU2009144972A (ru) * | 2007-05-04 | 2011-06-10 | Айронвуд Фармасьютикалз, Инк. (Us) | Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| KR20100049032A (ko) * | 2007-06-19 | 2010-05-11 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 부가 ｇｌｐ―１ 펩티드 |
| JP5478260B2 (ja) | 2007-12-05 | 2014-04-23 | 株式会社癌免疫研究所 | 癌ワクチン組成物 |
| GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| RU2518351C2 (ru) * | 2008-05-09 | 2014-06-10 | Эббви Дойчланд Гмбх Унд Ко.Кг, | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения |
| EP2296685B1 (en) | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP5604297B2 (ja) | 2008-06-17 | 2014-10-08 | 株式会社糖鎖工学研究所 | 糖鎖付加ｇｌｐ−１ペプチド |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20120213846A1 (en) * | 2008-08-15 | 2012-08-23 | Forest Laboratories Holdings Limited | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
| US20120039949A1 (en) * | 2008-09-04 | 2012-02-16 | Ironwood Pharmaceuticals, Inc. | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration |
| MX359570B (es) * | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| CA2743172A1 (en) * | 2008-11-19 | 2010-05-27 | Forest Laboratories Holdings Limited | Crystalline form of linaclotide |
| AU2009322285B2 (en) * | 2008-12-03 | 2016-07-28 | Bausch Health Ireland Limited | Formulations of guanylate cyclase C agonists and methods of use |
| AT507953B1 (de) | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
| WO2010115916A1 (en) * | 2009-04-10 | 2010-10-14 | F. Hoffmann-La Roche Ag | Process for isolating therapeutic peptide |
| HUE032582T2 (en) | 2009-05-20 | 2017-09-28 | Biomarin Pharm Inc | Variants of c-type natriuretic peptide |
| US8759299B2 (en) * | 2009-07-22 | 2014-06-24 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59 |
| US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| US20130045239A1 (en) | 2009-08-13 | 2013-02-21 | Ironwood Pharmaceuticals, Inc. | Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists |
| PH12012500916B1 (en) * | 2009-11-09 | 2018-03-23 | Ironwood Pharmaceuticals Inc | Treatments for gastrointestinal disorders |
| EP2509992B1 (en) | 2009-12-07 | 2015-10-14 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| KR101436222B1 (ko) * | 2009-12-14 | 2014-09-01 | 쉴 프로테인즈 게엠베하 | 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| WO2011103311A2 (en) * | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc | Treatments for gastrointestinal disorders |
| US9492508B2 (en) * | 2010-05-13 | 2016-11-15 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
| US9487570B2 (en) * | 2010-05-17 | 2016-11-08 | Betta Pharmaceuticals Co., Ltd | Glucagon like peptide analogs, composition, and method of use |
| RU2445965C2 (ru) * | 2010-07-05 | 2012-03-27 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Пероральная фармацевтическая композиция для лечения воспалительных заболеваний желудочно-кишечного тракта |
| NZ604805A (en) * | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
| HRP20192207T1 (hr) | 2010-08-11 | 2020-02-21 | Ironwood Pharmaceuticals, Inc. | Stabilne formulacije linaklotida |
| EP2621509A4 (en) | 2010-09-15 | 2016-08-03 | Synergy Pharmaceuticals Inc | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN113278077A (zh) * | 2010-11-26 | 2021-08-20 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| JP2014507400A (ja) * | 2010-12-22 | 2014-03-27 | ジーイー・ヘルスケア・リミテッド | Ｎｏｔａによって錯体化されたアルミニウム−［１８ｆ］フッ化物で標識されたｈｅｒ２結合ペプチド |
| CA3100941C (en) * | 2011-03-01 | 2024-03-05 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
| WO2012155114A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Peptides derived from uroguanylin and their use in gastrointestinal disorders |
| WO2012155108A1 (en) * | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for disorders using guanylate cyclase c agonists |
| US9650417B2 (en) | 2011-05-11 | 2017-05-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
| UA126465C2 (uk) * | 2011-06-10 | 2022-10-12 | Ханмі Сайенс Ко., Лтд. | Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить |
| KR102066987B1 (ko) * | 2011-06-10 | 2020-01-16 | 노보 노르디스크 에이/에스 | 폴리펩티드 |
| PL2721062T3 (pl) | 2011-06-17 | 2019-05-31 | Hanmi Science Co Ltd | Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| HUE032237T2 (en) | 2011-08-17 | 2017-09-28 | Ironwood Pharmaceuticals Inc | Treatments for gastrointestinal disorders |
| WO2013055251A1 (ru) * | 2011-10-14 | 2013-04-18 | Общество С Ограниченной Ответственностью "Цитонир" | Пероральная фармацевтическая композиция для лечения воспалительных заболеваний желудочно-кишечного тракта |
| WO2014088623A1 (en) * | 2012-07-12 | 2014-06-12 | Forest Laboratories Holdings Limited | Linaclotide compositions |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014041505A1 (en) * | 2012-09-13 | 2014-03-20 | Universite De Geneve | Cell penetrating peptides |
| US10155792B2 (en) | 2012-09-25 | 2018-12-18 | Affibody Ab | Albumin binding polypeptide |
| PT2916819T (pt) | 2012-11-06 | 2019-10-28 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina. |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| CN105658661B (zh) * | 2013-02-20 | 2020-07-24 | 卑尔根技术交易股份公司 | 疫苗 |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| KR20160042039A (ko) | 2013-08-09 | 2016-04-18 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| EP3083675B1 (en) | 2013-12-20 | 2018-03-07 | Affibody AB | Engineered albumin binding polypeptide |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| DK3356411T3 (da) | 2015-10-02 | 2021-09-06 | Hoffmann La Roche | Bispecifikke antistoffer, der er specifikke for PD1 og TIM3 |
| US11103592B2 (en) * | 2016-11-09 | 2021-08-31 | Philogen S.P.A. | IL2 and TNF mutant immunoconjugates |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| RU2769513C2 (ru) * | 2017-01-05 | 2022-04-01 | Кахр Медикал Лтд. | Слитый белок pd1-4-1bbl и способы его применения |
| PL3556378T3 (pl) | 2017-01-27 | 2025-06-09 | StemRIM Inc. | Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca |
| EP4201953A1 (en) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| CN110662762A (zh) | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
| US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
| CN118460462A (zh) | 2017-12-01 | 2024-08-09 | 斯特姆里姆有限公司 | 外胚层间充质干细胞及其产生方法 |
| WO2019156137A1 (ja) | 2018-02-08 | 2019-08-15 | 株式会社ステムリム | 乾癬の治療薬 |
| CA3104778A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EP3841111A1 (en) | 2018-08-24 | 2021-06-30 | Vestlandets Innovasjonsselskap AS | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
| US12246024B2 (en) | 2019-12-13 | 2025-03-11 | Free State Pharma Inc | Compositions and methods for controlling cerumen production |
Family Cites Families (585)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB290795A (en) | 1927-04-08 | 1928-05-24 | British Colour Printing Compan | Improvements in or relating to advertising or display devices |
| DE1116676B (de) | 1955-03-14 | 1961-11-09 | Thomae Gmbh Dr K | Verfahren zur Herstellung von Pyrimido [5, 4-d] pyrimidinen |
| GB1051218A (enExample) | 1963-03-09 | |||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3636039A (en) | 1970-02-24 | 1972-01-18 | Hoffmann La Roche | Substituted benzylimidazolidinones |
| GB1361441A (en) | 1970-05-13 | 1974-07-24 | Sandoz Ltd | Benzonaphthyridine derivatives |
| GB1338235A (en) | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| BE794964A (fr) | 1972-02-04 | 1973-08-02 | Bristol Myers Co | Nouveaux agents hypotenseurs et procede pour les preparer |
| JPS5229318B2 (enExample) | 1972-03-30 | 1977-08-01 | ||
| DE2305339C3 (de) | 1973-02-03 | 1980-05-08 | Dr. Karl Thomae Gmbh, 7950 Biberach | Imidazo [4,5-b] pyridine, ihre Herstellung und ihre Verwendung als Cardiötonica |
| AR205004A1 (es) | 1973-10-30 | 1976-03-31 | Ishikawa M | Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona |
| GB1491510A (en) | 1973-12-14 | 1977-11-09 | Hisamitsu Pharmaceutical Co | 1-nitrophenylquinazoline-2,4(1h,3h)-diones |
| DE2462367A1 (de) | 1974-01-22 | 1976-11-11 | Wuelfing J A Fa | 7-(oxoalkyl)-1,3-dialkylxanthine enthaltende arzneimittelzubereitungen |
| DE2413935A1 (de) | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
| US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
| US4072746A (en) | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
| JPS608117B2 (ja) | 1977-02-08 | 1985-02-28 | 財団法人微生物化学研究会 | 新生理活性物質エステラスチンおよびその製造法 |
| NZ187452A (en) | 1977-06-10 | 1980-05-27 | Otsuka Pharma Co Ltd | N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation |
| DE2727481A1 (de) | 1977-06-18 | 1979-01-11 | Basf Ag | Dihydropyridazone und dihydropyridazone enthaltende therapeutische mittel |
| NL7807507A (nl) | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
| CA1114379A (en) | 1977-11-03 | 1981-12-15 | Pfizer Corporation | Piperidino-phthalazines |
| US4220584A (en) | 1978-01-30 | 1980-09-02 | Merck & Co., Inc. | E. coli enterotoxin vaccine for veterinary and human use |
| JPS5527105A (en) | 1978-08-11 | 1980-02-27 | Dai Ichi Seiyaku Co Ltd | Imidazothienopyrimidinones compound |
| DE2837161A1 (de) | 1978-08-25 | 1980-03-06 | Thomae Gmbh Dr K | Neue benzimidazole und deren verwendung |
| JPS5535019A (en) | 1978-09-01 | 1980-03-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2845220A1 (de) | 1978-10-17 | 1980-04-30 | Yoshitomi Pharmaceutical | Pyridazinon-derivate, ihre salze mit saeuren, verfahren zu ihrer herstellung und ihre verwendung bei der behandlung von thrombosen und hypertonie |
| DE2847693A1 (de) | 1978-11-03 | 1980-05-22 | Hoechst Ag | Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen |
| NZ193935A (en) | 1979-06-18 | 1985-05-31 | Richardson Merrell Inc | 4-aroyl-imidazol-2-one derivatives;pharmaceutical compositions |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4285391A (en) | 1979-08-29 | 1981-08-25 | Aladdin Industries, Incorporated | Electrical system for food service devices |
| GB2063249A (en) | 1979-10-09 | 1981-06-03 | Mitsubishi Yuka Pharma | 4-Phenylphthalazine derivatives |
| IL61501A (en) | 1979-11-26 | 1984-06-29 | Sterling Drug Inc | 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
| JPS5777676A (en) | 1980-10-31 | 1982-05-15 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4405628A (en) | 1981-03-05 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Pyridylimidazolones and method of use |
| ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
| US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
| HU190412B (en) | 1981-09-17 | 1986-09-29 | Warner-Lambert Co,Us | Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones |
| EP0096517A3 (en) | 1982-06-05 | 1985-04-03 | Smith Kline & French Laboratories Limited | Aryl pyrazinones |
| DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
| US4886663A (en) | 1983-01-03 | 1989-12-12 | Scripps Clinic And Research Foundation | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli and multimers thereof |
| US4545931A (en) | 1983-01-03 | 1985-10-08 | Scripps Clinic And Research Foundation | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli |
| US4490371A (en) | 1983-02-16 | 1984-12-25 | Syntex (U.S.A.) Inc. | N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| GB8400863D0 (en) | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| GB8406906D0 (en) | 1984-03-16 | 1984-04-18 | Akzo Nv | Benzo-thiazole and benzothiophene derivatives |
| DK159431C (da) | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
| GR851085B (enExample) | 1984-05-12 | 1985-11-25 | Boehringer Mannheim Gmbh | |
| IL75122A (en) | 1984-05-14 | 1989-02-28 | Lilly Co Eli | 3-methyl-5-(tetrahydro-6-oxopyridazin-3-yl)indoline derivatives,their preparation and use |
| DE3424685A1 (de) | 1984-07-05 | 1986-02-06 | Beiersdorf Ag, 2000 Hamburg | Neue substituierte phenylpiperazinyl-propanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| JPS61218589A (ja) | 1985-03-26 | 1986-09-29 | Eisai Co Ltd | ５―（６―イミダゾ〔１，２―ａ〕ピリジニル）ピリジン誘導体 |
| DE3522638A1 (de) | 1985-06-25 | 1987-01-08 | Diamalt Ag | Neue somatostatin-derivate |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| ZW20586A1 (en) | 1985-10-17 | 1988-05-25 | Smith Kline French Lab | Chemical compounds |
| DE3614833A1 (de) | 1986-01-16 | 1987-07-23 | Hoechst Ag | Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| HU215433B (hu) | 1986-04-29 | 2000-05-28 | Pfizer Inc. | Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására |
| PT85521B (pt) | 1986-08-11 | 1990-06-29 | Innovata Biomed Ltd | Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas |
| ES2033922T3 (es) | 1986-08-28 | 1993-04-01 | Sandoz Ag | Procedimiento para preparar nuevos derivados de xantina. |
| HU906341D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| NZ222843A (en) | 1986-12-22 | 1989-10-27 | Ortho Pharma Corp | Benzoxazinyl- and benzothiazinyl-tetrahydropyridazinones and intermediates, and medicaments |
| GB8630702D0 (en) | 1986-12-23 | 1987-02-04 | Wellcome Found | Quinoline compound |
| CA1303037C (en) | 1987-02-02 | 1992-06-09 | Smith Kline & French Laboratories Limited | Purinone derivatives as bronchodilators vasodilators and anti-allergic agents |
| IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| AU614965B2 (en) | 1987-06-06 | 1991-09-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiadiazinones |
| NZ225447A (en) | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| IT1223343B (it) | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
| EP0326151B1 (en) | 1988-01-29 | 1993-06-16 | Sumitomo Pharmaceuticals Company, Limited | Improved controlled release formulation |
| JP2717687B2 (ja) | 1988-02-13 | 1998-02-18 | 日本曹達株式会社 | ピリダジノン誘導体及びその製造方法 |
| US5142096A (en) | 1988-03-31 | 1992-08-25 | Kyowa Hakko Kogyo Co., Ltd. | 2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds |
| DK163689A (da) | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| DE3910667A1 (de) | 1988-04-11 | 1989-10-19 | Sandoz Ag | Peptidderivate |
| JP2792862B2 (ja) | 1988-07-30 | 1998-09-03 | 寛治 高田 | 経口腸溶製剤 |
| NO893088L (no) | 1988-08-18 | 1990-02-19 | Syntex Inc | Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser. |
| BE1003762A3 (fr) | 1988-11-11 | 1992-06-09 | Sandoz Sa | Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives. |
| IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| CA2050905A1 (en) | 1989-02-23 | 1990-08-24 | George R. Felt | Therapeutic aerosol formulations |
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| JPH03505334A (ja) | 1989-04-11 | 1991-11-21 | イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド | 凍結乾燥されたペプチド製剤 |
| ES2075202T3 (es) | 1989-04-17 | 1995-10-01 | Byk Gulden Lomberg Chem Fab | Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen. |
| IT8920486A0 (it) | 1989-05-12 | 1989-05-12 | Isf Spa | Composizioni farmaceutiche. |
| NZ234186A (en) | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
| GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| CH679207A5 (enExample) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| HU215441B (hu) | 1989-11-13 | 1999-04-28 | Pfizer Inc. | Eljárás az endo-biciklo [2.2.1]-heptan-2-ol előállítására és az ebből kapott hatóanyagok enzimatikus úton történő elválasztására |
| US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
| ATE131471T1 (de) | 1989-12-22 | 1995-12-15 | Commw Scient Ind Res Org | An fette gebundene aminosäuren, peptide oder deren derivate |
| GB8929208D0 (en) | 1989-12-27 | 1990-02-28 | Almirall Lab | New xanthine derivatives |
| US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| HU208124B (en) | 1990-04-25 | 1993-08-30 | Nissan Chemical Ind Ltd | Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient |
| MY105344A (en) | 1990-05-16 | 1994-09-30 | Byk Gulden Lomberg Chemische Fabrik | New sulphonyl compounds |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| MC2311A1 (fr) | 1990-07-10 | 1993-09-27 | Smithkline Beecham Corp | Oxamides |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5124455A (en) | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| EP0553174B1 (de) | 1990-10-16 | 1998-07-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Arylpyridazinone |
| GB9027055D0 (en) | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
| JPH04234389A (ja) | 1990-12-28 | 1992-08-24 | Sapporo Breweries Ltd | ナフチリジン誘導体及びそれを有効成分とする抗潰瘍剤 |
| US5141931A (en) | 1991-01-03 | 1992-08-25 | Sterling Winthrop Inc. | 5-Quinolinylpyridinones, cardiotonic compositions and methods |
| IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| IE73235B1 (en) | 1991-03-25 | 1997-05-21 | Akzo Nv | 4-aryl-thiazole or imidazole derivatives |
| FR2674849B1 (fr) | 1991-04-02 | 1994-12-23 | Logeais Labor Jacques | Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique. |
| EP0510562A1 (de) | 1991-04-26 | 1992-10-28 | Byk Gulden Lomberg Chemische Fabrik GmbH | Neue Pyridazine |
| US5191084A (en) | 1991-05-01 | 1993-03-02 | American Home Products Corporation | Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| GB9116039D0 (en) | 1991-07-25 | 1991-09-11 | Ucb Sa | Substituted cyclopropylamino-1,3,5-triazines |
| US5140102A (en) * | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| JP3245165B2 (ja) | 1991-10-09 | 2002-01-07 | シンテックス（ユー・エス・エイ）・インコーポレイテッド | ピリドピリダジノンおよびピリダジンチオン化合物 |
| ATE165977T1 (de) | 1991-12-30 | 1998-05-15 | Neurex Corp | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
| US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
| WO1993015044A1 (en) | 1992-01-29 | 1993-08-05 | Smithkline Beecham Corporation | N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as tnf and pde iv inhibitors |
| AU3481593A (en) | 1992-01-29 | 1993-09-01 | Smithkline Beecham Corporation | N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives |
| GB9204808D0 (en) | 1992-03-04 | 1992-04-15 | Rhone Poulenc Rorer Ltd | Novel compositions of matter |
| US5264437A (en) | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
| US5602173A (en) | 1992-04-02 | 1997-02-11 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| EP0633771A4 (en) | 1992-04-02 | 1995-02-22 | Smithkline Beecham Corporation | Compounds. |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| ATE150447T1 (de) | 1992-06-15 | 1997-04-15 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
| US5969097A (en) * | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| ES2227519T3 (es) | 1992-07-28 | 2005-04-01 | Aventis Pharma Limited | Inhibidores de c-amp-fosfodiesterasa. |
| ATE178210T1 (de) | 1992-09-14 | 1999-04-15 | Forssmann Wolf Georg Prof Dr | Neue verwendung von inhibitoren der phosphodiesterase iv |
| JP3756512B2 (ja) | 1992-09-21 | 2006-03-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 徐放性タンパク質製剤 |
| US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
| BR9307570A (pt) | 1992-12-02 | 1999-05-25 | Pfizer | Diéteres de catecol como inibidores seletivos de pdeiv |
| US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| TW263495B (enExample) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| JPH08505395A (ja) | 1993-01-06 | 1996-06-11 | キナートン リミティド | 生物分解性ポリエステルと生物活性ポリペプチドのイオン分子結合体 |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| EP0679157B1 (en) | 1993-01-15 | 1997-11-19 | G.D. Searle & Co. | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
| US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| GB9309324D0 (en) | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| CA2161789A1 (en) | 1993-05-13 | 1994-11-24 | Jacques Yves Gauthier | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
| US5395490A (en) * | 1993-05-14 | 1995-03-07 | Intertec, Ltd. | Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies |
| US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| GB9311282D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| JPH0710875A (ja) | 1993-06-21 | 1995-01-13 | Green Cross Corp:The | 選択的ホスホジエステラーゼｉｖ阻害剤 |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| AU695301B2 (en) | 1993-07-06 | 1998-08-13 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines |
| ES2176251T3 (es) | 1993-07-28 | 2002-12-01 | Aventis Pharma Ltd | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). |
| GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
| US6300372B1 (en) | 1993-07-30 | 2001-10-09 | Smithkline Beecham Corporation | 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates |
| US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| HU224350B1 (hu) | 1993-08-09 | 2005-08-29 | Société de Conseils de Recherches et d'ApplicationScientifiques, S.A.S. Á | Gyógyhatású peptidszármazékok |
| JPH09502170A (ja) | 1993-08-19 | 1997-03-04 | スミスクライン・ビーチャム・コーポレイション | フェネチルアミン化合物 |
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| EP0727990B1 (en) | 1993-10-01 | 2001-06-13 | Smithkline Beecham Corporation | Compounds, compositions and treatment of allergies and inflammation |
| WO1995009623A1 (en) | 1993-10-01 | 1995-04-13 | Smithkline Beecham Corporation | Anti-allergic, anti-inflammatory compounds, compositions and uses |
| WO1995009836A1 (en) | 1993-10-01 | 1995-04-13 | Smithkline Beecham Corporation | Cyanocyclohexane compounds, compositions, and uses thereof |
| EP0722322B1 (en) | 1993-10-01 | 2001-11-14 | Smithkline Beecham Corporation | Compounds, compositions and treatment of allergies and inflammation therewith |
| ES2216004T3 (es) * | 1993-10-26 | 2004-10-16 | Thomas Jefferson University | Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas. |
| US5962220A (en) * | 1993-10-26 | 1999-10-05 | Thomas Jefferson University | Compositions that specifically bind to colorectal cells and methods of using the same |
| US5489670A (en) * | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| GB9322828D0 (en) | 1993-11-05 | 1993-12-22 | Sandoz Ltd | Organic compounds |
| EP0730587B1 (en) | 1993-11-26 | 1999-12-08 | Pfizer Inc. | 3-phenyl-2-isoxazolines as antiinflammatory agents |
| ATE154932T1 (de) | 1993-11-26 | 1997-07-15 | Pfizer | Isoxazolinverbindungen als entzündungshemmende mittel |
| US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
| RO118291B1 (ro) | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
| US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| ATE260911T1 (de) | 1993-12-22 | 2004-03-15 | Celltech R&D Ltd | Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe |
| GB9326699D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
| US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
| US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| JPH09510191A (ja) | 1994-02-17 | 1997-10-14 | アメリカン・ホーム・プロダクツ・コーポレイション | ホスホジエステラーゼ阻害薬としての置換ビフェニル誘導体 |
| CA2143143A1 (en) | 1994-03-08 | 1995-09-09 | Toshihiko Tanaka | 3-phenylpyrrolidine derivatives |
| GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
| WO1995027692A1 (en) | 1994-04-08 | 1995-10-19 | Smithkline Beecham Corporation | Subtituted biphenyl tnf inhibitors |
| US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
| WO1995028926A1 (en) | 1994-04-21 | 1995-11-02 | Schering Aktiengesellschaft | Pde iv inhibitors for treating multiple sclerosis |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| DK0685475T3 (da) | 1994-05-31 | 1999-08-30 | Bayer Ag | Amino-benzofuryl- og thienylderivater |
| HRP950288A2 (en) | 1994-05-31 | 1997-08-31 | Bayer Ag | Oxalylamino-benzofuran- and benzothienyl-derivatives |
| GB9410877D0 (en) | 1994-05-31 | 1994-07-20 | Bayer Ag | Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives |
| GB9412383D0 (en) | 1994-06-21 | 1994-08-10 | Celltech Ltd | Chemical compound |
| US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| CA2193725A1 (en) | 1994-06-24 | 1996-01-04 | David Cavalla | Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity |
| US5466697A (en) | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
| NZ290420A (en) | 1994-07-22 | 1999-01-28 | Byk Gulden Lomberg Chem Fab | Phenyl or pyridyl-amide substituted dihydro benzofurans; medicaments |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| WO1996011917A1 (en) | 1994-10-12 | 1996-04-25 | Euro-Celtique, S.A. | Novel benzoxazoles |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| PL321136A1 (en) | 1994-11-07 | 1997-11-24 | Pfizer | Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1 |
| EP0799218B1 (en) | 1994-12-21 | 2003-02-19 | Merck Frosst Canada & Co. | Diaryl-2-(5h)-furanones as cox-2 inhibitors |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| WO1996023514A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| CA2211664A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| ATE223390T1 (de) | 1995-02-13 | 2002-09-15 | Searle & Co | Substituierte isoxazole zur behandlung von entzündung |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
| US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
| US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US6054429A (en) | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
| ES2194998T3 (es) | 1995-06-27 | 2003-12-01 | Elan Pharm Inc | Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico. |
| US5795864A (en) | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5831108A (en) | 1995-08-03 | 1998-11-03 | California Institute Of Technology | High metathesis activity ruthenium and osmium metal carbene complexes |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| IL121070A (en) | 1995-10-12 | 2004-06-20 | Supergen Inc | LIPOSOME FORMULATIONS OF 5beta STEROIDS |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| DE69634416T2 (de) | 1995-11-24 | 2005-12-29 | Glaxosmithkline S.P.A. | Chinolin-derivate |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
| WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
| AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
| AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
| WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| AU1618697A (en) | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| JP3155013B2 (ja) | 1996-04-23 | 2001-04-09 | キナートン・リミテッド | 酸性ポリ乳酸ポリマー |
| CA2257206A1 (en) | 1996-06-07 | 1997-12-11 | Gui-Bai Liang | Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity |
| US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
| CZ433898A3 (cs) | 1996-07-03 | 1999-04-14 | Alza Corporation | Nevodné protické peptidové formulace |
| US5861398A (en) | 1996-08-26 | 1999-01-19 | Alanex Corporation | Benzoperimidine-carboxylic acids and derivatives thereof |
| WO1998011090A2 (en) | 1996-09-16 | 1998-03-19 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| CA2274594C (en) | 1996-12-16 | 2006-10-10 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
| US6100259A (en) | 1997-01-21 | 2000-08-08 | Smithkline Beecham Corporation | Cannabinoid receptor modulators |
| SK100099A3 (en) | 1997-01-28 | 2000-05-16 | Merck & Co Inc | Thiazole benzenesulfonamides as 'beta'3 agonists for the treatment of diabetes and obesity |
| CN1982290A (zh) | 1997-02-04 | 2007-06-20 | 阿肯色大学评议会 | 杀菌的羧酰胺 |
| US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| EP0966436B1 (de) | 1997-02-21 | 2002-12-11 | Bayer Aktiengesellschaft | Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| DE69812096T2 (de) | 1997-04-23 | 2003-10-30 | Banyu Pharmaceutical Co., Ltd. | Neuropeptid y rezeptorantagonisten |
| NZ329807A (en) | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
| US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
| SE9702457D0 (sv) | 1997-06-26 | 1997-06-26 | Pharmacia & Upjohn Ab | Screening |
| KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
| ATE273996T1 (de) | 1997-09-12 | 2004-09-15 | Pharis Biotec Gmbh | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
| US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| CA2326606A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | Aminoalkyl substituted 9h-pyridino[2,3-b]indole and 9h-pyrimidino[4,5-b]indole derivatives:crf1 and npy1 receptors |
| US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
| ID26128A (id) | 1998-04-29 | 2000-11-23 | Ortho Mcneil Pharm Inc | Senyawa-senyawa aminotetralin tersubstitusi-n sebagai ligan-ligan untuk reseptor neupeptida y y5 yang bermanfaat dalam pengobatan obesitas dan gangguan-gangguan lain |
| EE200000693A (et) | 1998-05-20 | 2002-04-15 | The Liposome Company, Inc. | Uudsed makroosakeste formulatsioonid |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| US6451349B1 (en) | 1998-08-19 | 2002-09-17 | Quadrant Healthcare (Uk) Limited | Spray-drying process for the preparation of microparticles |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| EP1098636A1 (en) | 1998-07-23 | 2001-05-16 | Novo Nordisk A/S | A wet granulation method for preparing a stable pharmaceutical formulation |
| AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| AU5911499A (en) | 1998-09-10 | 2000-04-03 | Millennium Pharmaceuticals, Inc. | Leptin induced genes |
| BR9913857A (pt) | 1998-09-17 | 2001-06-12 | Lilly Co Eli | Formulações de proteìna |
| US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| DE19844547C2 (de) | 1998-09-29 | 2002-11-07 | Aventis Pharma Gmbh | Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2000027845A1 (en) | 1998-11-10 | 2000-05-18 | Merck & Co., Inc. | Spiro-indolines as y5 receptor antagonists |
| ID29085A (id) | 1998-11-27 | 2001-07-26 | Kanji Takada | Suatu formulasi oral untuk penghantaran obat gastrointestinal |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| ES2161594B1 (es) | 1998-12-17 | 2003-04-01 | Servier Lab | Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
| US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
| US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
| IL144597A0 (en) | 1999-02-03 | 2002-05-23 | Powderject Res Ltd | Hydrogel particle formulations |
| WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
| US6344481B1 (en) | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| AU770235B2 (en) | 1999-03-08 | 2004-02-19 | Powderject Research Limited | Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds |
| WO2000054765A1 (en) | 1999-03-19 | 2000-09-21 | Knoll Gmbh | Method of treating eating disorders |
| US20010024664A1 (en) | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
| PL198797B1 (pl) | 1999-03-31 | 2008-07-31 | Janssen Pharmaceutica Nv | Zastosowanie wstępnie żelowanej skrobi |
| FR2792314B1 (fr) | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2002542183A (ja) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 成形可能な乾燥した医薬製剤 |
| US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
| DK1183245T3 (da) | 1999-04-22 | 2007-09-24 | Lundbeck & Co As H | Selektive NPY(Y5)-antagonister |
| HK1041263A1 (zh) | 1999-05-05 | 2002-07-05 | Ortho-Mcneil Pharmaceutical, Inc. | 可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体 |
| AU778393B2 (en) | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| WO2000074736A1 (en) | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| WO2001000221A2 (en) | 1999-06-23 | 2001-01-04 | Institut Pasteur | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| CA2380866A1 (en) | 1999-06-30 | 2001-01-11 | Synaptic Pharmaceutical Corporation | Selective npy (y5) antagonists |
| WO2001005757A2 (en) * | 1999-07-19 | 2001-01-25 | Nycomed Imaging As | Process for the deprotection of protected thiols |
| AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| HUP0202143A3 (en) | 1999-07-28 | 2003-12-29 | Ortho Mcneil Pharm Inc | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use |
| ES2209948T3 (es) | 1999-08-18 | 2004-07-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Formulacion de un peptico de liberacion sostenida. |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| WO2001013891A2 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
| WO2001021169A1 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Mch antagonists |
| OA12050A (en) | 1999-09-30 | 2006-05-02 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles. |
| YU23602A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini |
| KR20020047198A (ko) | 1999-09-30 | 2002-06-21 | 해피 페너 ; 해리 에이치. 페너 2세 | 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진 |
| WO2001025192A1 (en) | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| WO2001025266A1 (en) | 1999-10-06 | 2001-04-12 | Pharmacia Corporation | Uroguanylin as an intestinal cancer inhibiting agent |
| DE19949319A1 (de) | 1999-10-13 | 2001-06-13 | Ruetgers Vft Ag | Verfahren zur Herstellung von Arylalkylethern |
| AP2002002481A0 (en) | 1999-10-13 | 2002-06-30 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors. |
| PT1225897E (pt) | 1999-11-01 | 2005-01-31 | John Rhodes | Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel |
| BR0015322A (pt) | 1999-11-05 | 2002-07-09 | Aventis Pharma Gmbh | Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos |
| IL149872A0 (en) | 1999-12-16 | 2002-11-10 | Schering Corp | Substituted imidazole neuropeptide y y5 receptor antagonists |
| AU775905B2 (en) | 1999-12-31 | 2004-08-19 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| AU784226B2 (en) | 1999-12-31 | 2006-02-23 | Rutgers, The State University | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| JP2003520210A (ja) | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス， インコーポレイテッド | 低い水溶性を有する薬物の送達のための薬学的処方物 |
| US20030064105A1 (en) | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US6693165B2 (en) | 2000-01-18 | 2004-02-17 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| ES2220724T3 (es) | 2000-01-20 | 2004-12-16 | Basilea Pharmaceutica Ag | Composiciones de peptidos ciclicos administrables por via nasal. |
| US6645959B1 (en) | 2000-01-26 | 2003-11-11 | Warner-Lambert Company | Method for treating postoperative ileus |
| AU2001228325A1 (en) | 2000-02-01 | 2001-08-14 | Novo-Nordisk A/S | Use of compounds for the regulation of food intake |
| AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| JP2001226269A (ja) | 2000-02-18 | 2001-08-21 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| GB0004003D0 (en) | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| US7064142B2 (en) | 2000-02-22 | 2006-06-20 | Banyu Pharmaceutical, Co., Ltd. | Imidazonline compounds |
| HRP20020688A2 (en) | 2000-02-23 | 2004-12-31 | Aventis Pharma Gmbh | 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| DE50100558D1 (de) | 2000-02-26 | 2003-10-02 | Aventis Pharma Gmbh | 8,8a-dihydro-indeno 1,2-d]thiazol-derivate, die in 2-stellung einen substituenten mit einer sulfonamidstruktur oder sulfonstruktur tragen; verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| AU3580001A (en) | 2000-03-01 | 2001-09-12 | University College London | Modulators of the endocannabinoid uptake and of the vallinoid receptors |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| AU6011301A (en) | 2000-03-14 | 2001-09-24 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinoline derivatives |
| EP1268000A4 (en) | 2000-03-23 | 2004-12-29 | Merck & Co Inc | SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS |
| EP1268449A4 (en) | 2000-03-23 | 2004-09-15 | Merck & Co Inc | SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS |
| JP2004500401A (ja) | 2000-03-23 | 2004-01-08 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体 |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| EP1142886A1 (en) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Percyquinnin, a process for its production and its use as a pharmaceutical |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| CA2406206C (en) | 2000-04-17 | 2012-03-20 | Vectura Limited | Improvements in or relating to formulations for use in inhaler devices |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| CA2406947A1 (en) | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| AU2001263021A1 (en) | 2000-05-10 | 2001-11-20 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
| US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
| US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
| JP2004507456A (ja) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| CA2408913A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| JP2002371059A (ja) | 2000-05-16 | 2002-12-26 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| EP1286697A2 (en) | 2000-05-17 | 2003-03-05 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| US20020155084A1 (en) | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| WO2001093854A1 (en) | 2000-06-07 | 2001-12-13 | Alteon, Inc. | Method for treating hyperglycemia |
| AU6690001A (en) | 2000-06-15 | 2001-12-24 | Schering Corp | Thrombin receptor antagonists |
| AU2001272476A1 (en) | 2000-06-16 | 2001-12-24 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| CA2384041A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmaceuticals Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| EP1303509B1 (en) | 2000-07-13 | 2012-11-28 | Eli Lilly And Company | Beta3 adrenergic agonists |
| FR2811884B1 (fr) | 2000-07-21 | 2003-01-31 | Oreal | Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques |
| AU2001283938A1 (en) | 2000-07-24 | 2002-02-05 | Ardana Bioscience Limited | Ghrelin antagonists |
| DE60113865T2 (de) | 2000-07-31 | 2006-07-20 | Vernalis Research Ltd., Winnersh | Piperazin derivate |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| AU2001283573A1 (en) | 2000-08-21 | 2002-03-04 | Gliatech, Inc. | The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity |
| AU2001288294A1 (en) | 2000-08-21 | 2002-03-04 | Merck And Co., Inc. | Anti-hypercholesterolemic drug combination |
| US20020037829A1 (en) | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
| CA2419310A1 (en) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| AU2001290678A1 (en) | 2000-09-08 | 2002-03-22 | Powderject Research Limited | Alginate particle formulation |
| CN1474810A (zh) | 2000-09-14 | 2004-02-11 | ���鹫˾ | 取代脲,神经肽yy5受体拮抗剂 |
| WO2002026248A1 (en) | 2000-09-29 | 2002-04-04 | Cognetix, Inc. | Stable peptide formulations |
| HUP0301351A3 (en) | 2000-10-13 | 2007-05-29 | Lilly Co Eli | Use of substituted dipeptides as growth hormone secretagogues, process for their preparation and pharmaceutical compositions containing them |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| JP4047723B2 (ja) | 2000-10-16 | 2008-02-13 | エフ．ホフマン−ラ ロシュ アーゲー | インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用 |
| CA2423792A1 (en) | 2000-10-20 | 2002-04-25 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| WO2002036596A2 (en) | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| ATE329901T1 (de) | 2000-11-10 | 2006-07-15 | Lilly Co Eli | 3-substituierte oxindolderivate als beta-3- agonisten |
| NZ525700A (en) | 2000-11-20 | 2004-12-24 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor |
| CA2428905A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | PIPERAZINYLPYRAZINE COMPOUNDS FOR USE AS ANTAGONISTS OF THE SEROTONIN 5-HT2 RECEPTOR |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| EP1347982B1 (en) | 2000-12-12 | 2005-11-16 | Neurogen Corporation | Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| FI20002768L (fi) | 2000-12-18 | 2002-06-19 | Licentia Oy | Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus |
| DE60136562D1 (de) | 2000-12-21 | 2008-12-24 | Schering Corp | Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten |
| EP1216707B1 (en) | 2000-12-22 | 2005-02-09 | Institut Pasteur | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
| NZ525723A (en) | 2000-12-22 | 2004-11-26 | Schering Corp | 1,4-di-substituted piperidine antagonists for melanin-concentrating hormone (MCH) and their use in the treatment of obesity or diabetes |
| WO2002051806A1 (en) | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| EP1347979B1 (en) | 2000-12-27 | 2007-08-08 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| JP2004524297A (ja) | 2001-01-23 | 2004-08-12 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニスト |
| EP1370558B1 (en) | 2001-01-23 | 2005-08-24 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| WO2002059107A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
| WO2002058672A2 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| PE20021002A1 (es) | 2001-02-02 | 2002-12-06 | Takeda Chemical Industries Ltd | Compuestos heterociclicos condensados |
| AU2002235520A1 (en) | 2001-02-02 | 2002-08-19 | Pharmacia Corporation | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| PT1372708E (pt) | 2001-02-13 | 2008-09-29 | Us Gov Sec Army | Vacina para imunização transcutânea |
| KR20020066778A (ko) | 2001-02-13 | 2002-08-21 | 한국과학기술연구원 | 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법 |
| GEP20053710B (en) | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
| EP1372653B1 (en) | 2001-02-28 | 2006-10-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| JP2004523559A (ja) | 2001-02-28 | 2004-08-05 | スミスクライン ビーチャム コーポレーション | 過敏性腸症候群および機能性胃腸症の治療方法 |
| EP1385506B1 (en) | 2001-02-28 | 2009-05-06 | Merck & Co., Inc. | Acylated piperidine derivates as melanocortin-4 receptor agonists |
| GB0105772D0 (en) | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
| US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
| EP1383376A4 (en) | 2001-03-19 | 2006-03-08 | Praecis Pharm Inc | PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE |
| US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| KR20030093257A (ko) | 2001-03-21 | 2003-12-06 | 파마코페이아, 인크. | Ｍｃｈ 조정 활성을 지닌 아릴 및 바이아릴 화합물 |
| GB0107106D0 (en) | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
| ATE284872T1 (de) | 2001-03-22 | 2005-01-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung |
| AU782148B2 (en) | 2001-03-29 | 2005-07-07 | Molecular Design International, Inc. | Beta3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
| JP4206272B2 (ja) | 2001-03-29 | 2009-01-07 | サイナージィ ファーマスーティカルズ、インコーポレイテッド | 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト |
| EP1451211A2 (en) | 2001-03-30 | 2004-09-01 | University of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| GB0108631D0 (en) | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| ATE460163T1 (de) | 2001-04-12 | 2010-03-15 | Pharmacopeia Llc | Arly und diaryl piperidinderivate verwendbar als mch-hemmer |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| IL158418A0 (en) | 2001-04-19 | 2004-05-12 | Scripps Research Inst | In vivo incorporation of unnatural amino acids |
| WO2002088095A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| CZ20032990A3 (cs) | 2001-05-05 | 2004-04-14 | Smithkline Beecham P. L. C. | N-aroylové cyklické aminy |
| WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| MY134211A (en) | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
| KR100621287B1 (ko) | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 |
| DE60215637T2 (de) | 2001-05-21 | 2007-08-23 | Neurocrine Biosciences, Inc., San Diego | Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten |
| IL158941A0 (en) | 2001-05-22 | 2004-05-12 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| AU2002316771A1 (en) * | 2001-06-05 | 2002-12-16 | Yalcin Cetin | Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems |
| EP1406872B1 (en) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| DE60209348T2 (de) | 2001-06-20 | 2006-10-12 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| WO2003002593A2 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
| WO2003004062A1 (en) | 2001-07-02 | 2003-01-16 | Sarlan, Ltd. | Pharmaceutical formulations and ligands for use therein; mimetics for uea-1 |
| EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| IL159697A0 (en) | 2001-07-05 | 2004-06-20 | Synaptic Pharma Corp | Substituted anilinic piperidines as mch selective antagonists |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| US6960646B2 (en) | 2001-07-12 | 2005-11-01 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptors agonists |
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| IL159643A0 (en) | 2001-07-26 | 2004-06-01 | Schering Corp | Substituted urea neuropeptide y y5 receptor antagonists |
| US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
| JP4301940B2 (ja) | 2001-07-31 | 2009-07-22 | 日清オイリオグループ株式会社 | 抗肥満剤およびその原料 |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| WO2003014113A1 (en) | 2001-08-06 | 2003-02-20 | Glenmark Pharmaceuticals Limited | Novel benzopyran compounds and process for their preparation and use |
| US7205417B2 (en) | 2001-08-07 | 2007-04-17 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| CA2456964A1 (en) | 2001-08-08 | 2003-02-20 | Merck & Co., Inc. | Melanin-concentrating hormone antagonists |
| US6790462B2 (en) | 2001-08-09 | 2004-09-14 | Rhodia Inc. | Calcium dietary supplement |
| WO2003014304A2 (en) | 2001-08-09 | 2003-02-20 | Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International | Protonic formulation |
| WO2003016276A2 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | 3-substituted oxindole beta-3 agonists |
| DE60215028T2 (de) | 2001-08-14 | 2007-03-15 | Eli Lilly And Co., Indianapolis | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes |
| EP1418890B1 (en) | 2001-08-16 | 2008-05-14 | Baxter International Inc. | Propellant-based microparticle formulations |
| DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20030092041A1 (en) | 2001-08-23 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Novel use for muscarinic receptor M5 in the diagnosis and treatment of metabolic disorders |
| WO2004019872A2 (en) | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| BR0212256A (pt) | 2001-08-30 | 2004-08-31 | Biorexis Pharmaceutical Corp | Proteìnas de fusão de transferrina modificadas |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| AU2002331766A1 (en) | 2001-08-31 | 2003-03-18 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| US6915444B2 (en) | 2001-09-12 | 2005-07-05 | Rockwell Automation Technologies, Inc. | Network independent safety protocol for industrial controller using data manipulation techniques |
| EP1426370A4 (en) | 2001-09-13 | 2009-12-23 | Nisshin Pharma Inc | PROPANOLAMINE DERIVATIVE WITH 1,4-BENZODIOXANRING |
| EP1430027B1 (en) | 2001-09-14 | 2010-09-01 | High Point Pharmaceuticals, LLC | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| EP1426366A4 (en) | 2001-09-14 | 2004-12-08 | Mitsubishi Pharma Corp | THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE |
| ATE450508T1 (de) | 2001-09-14 | 2009-12-15 | High Point Pharmaceuticals Llc | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren |
| MXPA04001785A (es) | 2001-09-14 | 2004-07-08 | Bayer Ag | Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores. |
| EP1463727A2 (en) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| ES2272809T3 (es) | 2001-09-21 | 2007-05-01 | Solvay Pharm Bv | Nuevos derivados de 4,5-dihidro-1h-pirazol con actividad antagonista de cb1. |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| US6974810B2 (en) | 2001-09-21 | 2005-12-13 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
| US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| GT200200188A (es) | 2001-09-24 | 2003-06-25 | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
| PL205971B1 (pl) | 2001-09-24 | 2010-06-30 | Imp Innovations Ltd | Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości |
| WO2003026576A2 (en) | 2001-09-24 | 2003-04-03 | Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College | Induction of brown adipocytes by transcription factor nfe2l2 |
| MXPA04002438A (es) | 2001-09-24 | 2004-06-29 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad. |
| WO2003027114A1 (en) | 2001-09-24 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| US6787558B2 (en) | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| AU2002334733B2 (en) | 2001-10-01 | 2006-11-23 | Arena Pharmaceuticals, Inc. | MCH receptors antagonists |
| DE60226756D1 (de) | 2001-10-04 | 2008-07-03 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| US6667322B2 (en) | 2001-10-05 | 2003-12-23 | Wyeth | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole |
| FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
| EP1465867A1 (en) | 2001-10-09 | 2004-10-13 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| BR0213208A (pt) | 2001-10-09 | 2004-08-31 | Upjohn Co | Compostos de tetraidro- e hexaidro-carbazóis de arilsulfonila substituìda, suas composições e usos |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US20050014805A1 (en) | 2001-10-12 | 2005-01-20 | Chenzhi Zhang | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| EP1438045B1 (en) | 2001-10-23 | 2007-02-14 | Biovitrum Ab | Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake |
| CN1585751A (zh) | 2001-10-25 | 2005-02-23 | 武田药品工业株式会社 | 喹啉化合物 |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| SE0103644D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
| GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| SE0103648D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinolone compounds |
| DE60232173D1 (de) | 2001-11-09 | 2009-06-10 | Biovitrum Ab Publ | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme |
| AU2002365892A1 (en) | 2001-11-30 | 2003-06-17 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
| DE60213851T2 (de) | 2001-12-04 | 2007-09-13 | F. Hoffmann-La Roche Ag | Ringannelierte pyrazolderivate |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| DE10160409A1 (de) | 2001-12-10 | 2003-06-18 | Guenther Beisel | Verwendung von ionischen und nichtionischen Celluloseethern zur Herstellung eines gelartigen Mittels zur Verhinderung der Resorption von Fetten aus dem Magen-Darm-Trakt |
| ES2295441T3 (es) | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
| EP1458708B1 (en) | 2001-12-18 | 2007-09-26 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| CN1606432A (zh) | 2001-12-19 | 2005-04-13 | 阿尔扎公司 | 用于增加亲水性大分子的口服生物利用度的制剂和剂型 |
| EP1458385A4 (en) | 2001-12-19 | 2005-12-21 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS |
| EP1458710A4 (en) | 2001-12-21 | 2005-04-20 | Merck & Co Inc | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| US20030129160A1 (en) | 2002-01-09 | 2003-07-10 | John-Olov Jansson | Use of Interleukin-6 |
| US20040121961A1 (en) * | 2002-02-04 | 2004-06-24 | Jaime Masferrer | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| AU2003224644A1 (en) | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| DE60327843D1 (de) | 2002-03-04 | 2009-07-16 | Ipsen Pharma | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid |
| CA2479350A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| ES2718455T3 (es) | 2002-03-20 | 2019-07-02 | Civitas Therapeutics Inc | Formulaciones terapéuticas sostenidas inhalables |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| SE0201175L (sv) | 2002-04-18 | 2003-10-19 | Jonsered Cranes Ab | Kranarrangemangstillhörig hållarenhet |
| US20040015201A1 (en) | 2002-04-22 | 2004-01-22 | Transneuronix, Inc. | Process for electrostimulation treatment of obesity |
| PT1501534E (pt) | 2002-05-07 | 2006-09-29 | Ferring Bv | Formulacoes farmaceuticas |
| CN100411618C (zh) | 2002-05-17 | 2008-08-20 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
| US20060130158A1 (en) | 2002-08-30 | 2006-06-15 | Turner Andrew J | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| MXPA05005794A (es) | 2002-12-02 | 2005-08-16 | Hoffmann La Roche | Derivados de indazol como antagonistas del factor de liberacion de corticotropina. |
| US20040192680A1 (en) | 2002-12-20 | 2004-09-30 | Anderson Steven N. | Novel amides that activate soluble guanylate cyclase |
| US20060281682A1 (en) * | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ATE477268T1 (de) * | 2003-01-28 | 2010-08-15 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur behandlung von magen-darm- störungen |
| US6683072B1 (en) | 2003-02-04 | 2004-01-27 | Vela Pharmaceuticals, Inc. | Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia |
| EP1599165A4 (en) * | 2003-02-10 | 2010-09-08 | Univ Jefferson | THE USE OF GCC LIGANDS |
| BRPI0409986A (pt) | 2003-05-05 | 2006-05-09 | Hoffmann La Roche | derivados de pirimidina fundida com atividade de crf |
| CA2525273C (en) | 2003-05-16 | 2012-04-17 | Vela Pharmaceuticals, Inc. | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine |
-
2005
- 2005-02-08 US US11/054,071 patent/US7772188B2/en active Active
- 2005-03-08 WO PCT/US2005/007752 patent/WO2005087797A1/en not_active Ceased
- 2005-03-08 EP EP05732019A patent/EP1730172A4/en not_active Withdrawn
- 2005-03-08 BR BRPI0508558-6A patent/BRPI0508558A/pt not_active Application Discontinuation
- 2005-03-08 CA CA2558050A patent/CA2558050C/en active Active
- 2005-03-08 SG SG200904060-1A patent/SG153824A1/en unknown
- 2005-03-08 CN CN2010105277281A patent/CN102020704A/zh active Pending
- 2005-03-08 CN CNA200580014557XA patent/CN101010335A/zh active Pending
- 2005-03-08 AU AU2005222387A patent/AU2005222387B2/en not_active Expired
- 2005-03-08 MX MXPA06010205A patent/MXPA06010205A/es active IP Right Grant
- 2005-03-08 NZ NZ549519A patent/NZ549519A/en not_active IP Right Cessation
- 2005-03-08 EP EP09154673.9A patent/EP2088154B1/en not_active Revoked
- 2005-03-08 JP JP2007502956A patent/JP2008501310A/ja active Pending
- 2005-03-08 KR KR1020067020883A patent/KR101202727B1/ko not_active Expired - Lifetime
-
2006
- 2006-08-30 IL IL177772A patent/IL177772A0/en active IP Right Grant
- 2006-09-13 NO NO20064121A patent/NO335730B1/no unknown
-
2011
- 2011-03-22 JP JP2011063415A patent/JP5559087B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0508558A (pt) | 2007-08-07 |
| EP2088154B1 (en) | 2017-12-13 |
| KR20070007332A (ko) | 2007-01-15 |
| CN101010335A (zh) | 2007-08-01 |
| NO20064121L (no) | 2006-11-22 |
| NO335730B1 (no) | 2015-02-02 |
| EP1730172A4 (en) | 2009-01-14 |
| IL177772A0 (en) | 2006-12-31 |
| WO2005087797A1 (en) | 2005-09-22 |
| CA2558050A1 (en) | 2005-09-22 |
| JP2008501310A (ja) | 2008-01-24 |
| MXPA06010205A (es) | 2007-03-15 |
| US20090062207A1 (en) | 2009-03-05 |
| AU2005222387A1 (en) | 2005-09-22 |
| JP2011152140A (ja) | 2011-08-11 |
| AU2005222387B2 (en) | 2010-12-02 |
| CN102020704A (zh) | 2011-04-20 |
| KR101202727B1 (ko) | 2012-11-20 |
| EP2088154A1 (en) | 2009-08-12 |
| SG153824A1 (en) | 2009-07-29 |
| EP1730172A1 (en) | 2006-12-13 |
| US7772188B2 (en) | 2010-08-10 |
| JP5559087B2 (ja) | 2014-07-23 |
| CA2558050C (en) | 2013-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005222387B2 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| US7494979B2 (en) | Method for treating congestive heart failure and other disorders | |
| JP2008501310A6 (ja) | 胃腸障害の治療のための方法および組成物 | |
| US8779090B2 (en) | Methods and compositions for the treatment of heart failure and other disorders | |
| US20090253634A1 (en) | Methods and Compositions for the Treatment of Gastrointestinal Disorders | |
| CA2688161C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| CA2726913C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| US20090192083A1 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| US20120283411A9 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| US20090305993A1 (en) | Methods and composition for the treatment of gastrointestinal disorders | |
| CA2913737A1 (en) | Ultra-pure agonists of guanylate cyclase c, method of making and using same | |
| US20080025966A1 (en) | Methods And Compositions For The Treatment Of Gastrointestinal disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2016 BY CPA GLOBAL Effective date: 20150122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2017 BY CPA GLOBAL Effective date: 20160122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2018 BY CPA GLOBAL Effective date: 20170120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2019 BY CPA GLOBAL Effective date: 20180125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2020 BY CPA GLOBAL Effective date: 20190124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2021 BY CPA GLOBAL Effective date: 20200123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2022 BY CPA GLOBAL Effective date: 20210121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2023 BY CPA GLOBAL Effective date: 20220121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2024 BY CPA GLOBAL Effective date: 20230120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240125 |
|
| EXPY | Patent expired |